World Vaccines Congress India, Tuesday 19 September 2017



Organiser’s welcome remarks

Vikas Dandekar

Chairman’s opening remarks

Suja Chandy

Pharma Vision 2020, How close are we to the goal?

The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacturing. The Indian pharma market is expected to grow to US$ 55 billion by 2020. With the government implementing many new initiatives in its stride toward Pharma Vision 2020, how close are we to achieving it?
Panel discussion

Boardroom panel: Creating a robust ecosystem for pharma in India

India is poised to become a top 5 global pharmaceutical hub by 2020. But in order to achieve this, there’s work to be done, to develop a successful ecosystem. Key stakeholders including the government, pharma, regulators and investors need to work closely together to build it. In this panel, we gather them to explore how, as we explore issues including:
  • How will the creation of new pharma clusters across India help enhance the ecosystem?
  • How is the Indian government playing an active role to help build up the ecosystem? (Building infrastructure, funding of incubators and accelerators, mission mode programmes)
  • Should a robust and sustainable ecosystem be centred around academic institutes to increase collaboration?
  • What are some existing models which India can emulate? (Boston,SF Bay area, Singapore, BioValley)
  • Is achieving that too idealistic? How far is India from achieving that?

Speed Networking


Networking Refreshments & Exhibition Visit

Rodrigo Blanco Zamora

LatAm: Investment, market access, and reimbursement issues in this key regional growth market

  • Highlighting the potential within the LatAm pharmaceutical markets
  • Regulatory reforms and deregulation in Mexico
  • Updates on the practical implementation of Mexico as a regional reference agency for other LatAm countries
  • Advantages for the registration of biologic drugs in LatAm
  • What it takes to successfully launch biologics in LatAm and their various reimbursement infrastructure

Roundtable discussion


Table 1: Technology road mapping and industry collaboration in biologics manufacturing


Table 2: Single-Use Technology - qualification testing for the films used in flexible bags (BioProcess Containers)


Table 3: Innovative market access, RWE and HEOR strategies for emerging and mature products in India


Networking Lunch & Exhibition Visit

World Vaccines Congress India

Chair’s opening remarks

Vaccine Outlook

Sarthak Vasudeva
World Vaccines Congress India

Adult Vaccination in India: an untapped market potential?

  •     Exploring strategies to create awareness for need of adult vaccinations
  •     How should we approach the education of the population?
  •     Case study: Success models from the developed world
Panel discussion
World Vaccines Congress India

Sustainability of Vaccines Industry: Coping with pricing pressures

India is supplying more than 60% of the vaccines procured by GAVI. Vaccines in the public market are older and mass manufactured. Due to the cost of production, new vaccines are not able to enter the market. Should local vaccine manufacturers focus on ensuring cheap production of old vaccines for the public market or should they develop new vaccines for their private market instead? This session will explore differences between public & private markets, together with strategies for navigating the public market.
  • Comparing the differences between public and private market in terms of development and production cost
  • Understanding the differences in demands for both markets
  • What are some challenges that are unique to the public market? (E.g. Price pressures from GAVI, WHO)
  • Explore strategies in overcoming these challenges to achieve a sustainable model

Novel Vaccines Technologies


Networking Refreshments & Exhibition Visit

World Vaccines Congress India

Chair’s opening remarks

Arani Chatterjee
World Vaccines Congress India

Single-window clearance for vaccines approval in India

  •     Updates of discussions with regulators for single-window clearance
  •     How can companies work better together with regulators to streamline process? 
Paul Howley
World Vaccines Congress India

Case Study: Novel platform vector and CHO cell substrate technology

  •     Development of a novel vaccine delivery vehicle derived from vaccinia virus called SCV
  •     The cell substrate for the production of SCV is a genetically engineered CHO suspension cell line
  •     SCV has been used to develop protective vaccines for chikungunya and zika virus infection
Manoj Kumar Chhikara
World Vaccines Congress India

Synthetic conjugate vaccines: An overview

  •     Understanding the difference between traditional conjugate vaccines vs synthetic conjugate vaccines
  •     How do synthetic conjugates help in increasing product quality and reducing cost?
  •     Review of existing synthetic conjugate vaccines and ongoing research
  •     Presentation of preliminary data from MSD Wellcome Trust Hilleman Laboratories
Ted Fjallman
World Vaccines Congress India

Prokarium’s oral and thermostable Vaxonella platform to deliver a combination typhoid-paratyphoid vaccine

  •     Combination typhoid-paratyphoid vaccine
  •     Oral and thermostable
  •     Platform widely applicable to other indications
Nirav Desai
World Vaccines Congress India

Novel platform technologies for development and production of Vaccines

    style="font-size: 10.0pt;">
  •     Overview of the traditional vaccine technology
  •     Exploring new vaccine platforms in development, including recombinant, DNA, VLP, Live virus vectors and cancer vaccine
  •     Case study in CPL Biological

Networking Drinks Reception

last published: 18/Sep/17 06:35





To exhibit or sponsor call Pinky Fadullon on
+65 6322 2738 or email